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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by progressive worsening of airflow
limitation associated with abnormally inflamed airways in older smokers. Despite correlative evidence for a role for
tumor necrosis factor-alpha in the pathogenesis of COPD, the anti-tumor necrosis factor-alpha, infliximab did not
show clinical efficacy in a double-blind, placebo-controlled, phase II clinical trial. This study sought to evaluate the
systemic inflammatory profile associated with COPD and to assess the impact of tumor necrosis factor
neutralization on systemic inflammation.
Methods: Serum samples (n = 234) from the phase II trial were collected at baseline and after 24 weeks of
placebo or infliximab. Additionally, baseline serum samples were obtained from an independent COPD cohort (n =
160) and 2 healthy control cohorts (n = 50; n = 109). Serum concentrations of a broad panel of inflammation-
associated analytes were measured using a 92-analyte multiplex assay.
Results: Twenty-five proteins were significantly elevated and 2 were decreased in COPD, including highly elevated
CD40 ligand, brain-derived neurotrophic factor, epidermal growth factor, acute-phase proteins, and neutrophil-
associated proteins. This profile was largely independent of smoking status, age, and clinical phenotype. The
majority of these associations of serum analytes with COPD are novel findings. Increased serum creatine kinase-
muscle/brain and myoglobin correlated modestly with decreased forced expiratory volume at 1 second, suggesting
cardiac involvement. Infliximab did not affect this systemic inflammatory profile.
Conclusions: A robust systemic inflammatory profile was associated with COPD. This profile was generally
independent of disease severity. Because anti-tumor necrosis factor-alpha did not influence systemic inflammation,
how to control the underlying pathology beyond symptom suppression remains unclear.
Trial Registration: ClinicalTrials.gov, No.: NCT00056264.
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Background
Chronic obstructive pulmonary disease (COPD) is a
complex syndrome characterized by progressive expira-
tory airflow loss associated with abnormal inflammation
in the lungs. In addition to symptoms related to airway
pathology–including cough, excessive sputum, and dys-
pnea–COPD has systemic manifestations, one of which
may be exercise limitation related to muscle weakness
[1]. Systemic inflammation has been described in
COPD, including increased production of the potent
inflammatory mediator tumor necrosis factor (TNF)-
alpha [2-5]. Increased TNF-alpha production has also
been associated with muscle loss and weakness in
COPD [5-7]. Although no natural animal models of
COPD exist, intraperitoneal injection of TNF-alpha in
rats leads to emphysema,[8] which may resemble the
apoptosis of alveolar cells observed in COPD patients
with emphysema [9,10].
* Correspondence: Mloza@its.jnj.com
1Immunology Biomarkers, Janssen Research & Development, LLC, Malvern,
PA, USA
Full list of author information is available at the end of the article
Loza et al. Respiratory Research 2012, 13:12
http://respiratory-research.com/content/13/1/12
© 2012 Loza et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Because TNF-alpha inhibitors have demonstrated
clinical efficacy in various chronic inflammatory disor-
ders,[11-13] a phase II, double-blind, multicenter, pla-
cebo-controlled clinical study was performed to
evaluate the safety and efficacy of infliximab (Janssen
Biotech, Inc., Horsham, PA, USA), an anti-TNF-alpha
monoclonal antibody, in the treatment of COPD [14].
Infliximab failed to demonstrate improvement in the
primary endpoint, the Chronic Respiratory Question-
naire (CRQ) score, and in other secondary clinical out-
comes after 24 weeks of treatment. Serum samples
were obtained from patients at baseline and after 24
weeks of treatment.
The goal of this study was to test the hypothesis that
the lack of clinical efficacy of infliximab in COPD
patients was associated with a failure of infliximab to
significantly impact the underlying systemic inflamma-
tion associated with COPD. From previous pharmaco-
dynamic studies of infliximab, several serum
biomarkers, including MIP-1beta and TNF-RII, were
shown to be significantly decreased by anti-TNF treat-
ment, with changes in these biomarkers correlating
with clinical efficacy [15]. In addition, the general sys-
temic inflammatory and biochemical profile associated
with COPD was defined and evaluated for whether
infliximab treatment could impact this broader dis-
ease-associated profile.
Methods
Subjects
In the phase II, double-blind, multicenter, placebo-con-
trolled C0168T54 study (T54), COPD patients were ran-
domized, stratified by investigational site and smoking
status, to receive placebo or infliximab 3 or 5 mg/kg at
weeks 0 (baseline), 2, 6, 12, 18, and 24. Detailed back-
ground and results have been reported [14]. Peripheral
venous blood samples were collected in the T54 study
before study agent administration at baseline and at 24
weeks [14].
Additional serum samples from patients with mild-to-
severe COPD with available demographics and disease
characteristics data were purchased from a commercial
vendor (BioServe Biotechnologies, Ltd., Beltsville, MD,
USA) and evaluated according to Global Initiative for
Chronic Obstructive Lung Disease (GOLD) criteria.
Serum samples from 2 sets of healthy controls were
obtained from a commercial vendor (Bioreclamation,
LLC, Hicksville, NY, USA). Qualification for healthy sta-
tus is detailed in the online supplement (see Additional
file 1).
This study was conducted according to the principles
of the Declaration of Helsinki. The institutional review
board for each site in the T54 study approved the proto-
col. All subjects provided informed written consent.
Measurement of serum analyte concentrations
Serum samples were analyzed for the concentrations of
92 inflammation-associated proteins by Rules-Based
Medicine, Inc. (now Myriad RMB, Inc., Austin, TX,
USA) using their human MAP v1.6 panel of Luminex-
based multiplex assays. The analytes included in the
panel are listed in the online supplement Table S1 (see
Additional file 2). The handling of values below reliable
quantification (least detectable dose [LDD]) is described
in the online supplement (see Additional file 1). The
first set of healthy control samples (Ctr1) was bioana-
lyzed in the same batch as the T54 and BioServe sam-
ples. The second set of healthy control samples (Ctr2)
was bioanalyzed independently.
Statistical Analyses
Mann-Whitney U tests were used to compare continu-
ous variables among 2 groups. Fisher’se x a c tt e s t sw e r e
used to compare dichotomous variables. Rank-based
tests using Spearman’s correlations were used to test for
correlations among continuous variables. Significance
levels were reported as p-values or false discovery rates
(FDR) to control for multiple-testing inflation of false
positive rate (Benjamin-Hochberg procedure). Hierarchi-
cal standard clustering analyses were performed with
average linkage and a Euclidean similarity metric
(ArrayStudio, OmicSoft Corp., Cary, NC, USA).
Results
COPD and healthy control cohorts
Before examining whether infliximab treatment was able
to modify the systemic inflammatory and biochemical pro-
file in COPD patients, this systemic profile first needed to
be rigorously established in both the study population and
an independent COPD population compared to healthy
control populations. In the T54 study, 234 serum samples
were collected at baseline, and 200 samples were collected
after 24 weeks of treatment with placebo (n = 68) or inflix-
imab 3 mg/kg (n = 64) or 5 mg/kg (n = 68) from COPD
patients, most of whom had moderate-to-very severe dis-
ease (GOLD stages II-IV). One hundred sixty serum sam-
ples were obtained from BioServe from patients with
mild-to-very severe COPD distributed evenly across dis-
ease severities (GOLD stages I-IV). Fifty serum samples
were obtained from Ctr1, and 109 samples were obtained
from Ctr2. Demographic and clinical characteristics for
each cohort are reported in Table 1.
Associations of baseline serum analyte levels and COPD
Differences in analyte levels were tested separately for
each COPD cohort versus each control cohort for a
total of 4 individual comparisons per analyte. Twenty-
five serum analytes were significantly elevated by ≥ 50%
(FDR < 0.05 and fold/control > 1.50) in the COPD
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Page 2 of 12Table 1 Demographic and baseline clinical phenotypes in COPD and control populations
Parameter T54 COPD
a BioServe COPD
b Healthy controls
c p (COPD vs healthy control)
d
Total Placebo 3 mg/kg 5 mg/kg p-value Total p (vs T54) Ctr1 Ctr2 Ctr1 vs T54, BS Ctr2 vs T54, BS
Sample size (n) 234
e 68 64 68 160 50 109
Gender(n: male/female) 140/94 43/25 40/24 37/31 0.51 73/87 0.37 30/20 54/42 (1.0, 0.52) (0.27, 0.63)
Age (years) 65.2 ± 8.8 65.0 ± 8.9 64.4 ± 8.2 64.9 ± 9.6 0.93 65.8 ± 11.8 0.57 38.7 ± 11.8 49.9 ± 14.5 (< 10
-4,<1 0
-4)( < 1 0
-4,<1 0
-4)
BMI (kg/m
2) 27.2 ± 6.1 28.2 ± 6.1 26.6 ± 5.4 27.0 ± 6.6 0.32 26.5 ± 7.0 0.27 27.0 ± 6.8 27.9 ± 6.9 (0.82, 0.65) (0.46, 0.16)
Race (n) 0.46 0.036 (< 10
-4,<1 0
-4)( < 1 0
-4,<1 0
-4)
Black 10 3 1 4 14 25 41
Caucasian 223 64 63 64 143 5 22
Other 1 1 0 0 3 20 12
Smoking status (n) 0.93 0.00011 (< 10
-4,<1 0
-4)( < 1 0
-4,<1 0
-4)
Current smoker 104 29 29 31 50 33 36
Ex-smoker 130 39 35 37 100
Non-smoker 91 6 2 4
GOLD stage (n) 0.66 < 10
-9 n/a n/a n/a n/a
stage I 3 1 0 2 40
stage II 74 23 21 20 40
stage III 104 33 31 26 40
stage IV 53 11 16 16 40
Subtype (n) 0.58 < 10
-9 n/a n/a n/a n/a
Chronic bronchitis 54 20 11 15 41
Chronic emphysema 95 26 28 28 80
Both 85 22 25 25 3
FEV1 (% predicted)
Baseline 43.4 ± 16.0 45.2 ± 16.2 43.9 ± 17.5 41.8 ± 14.9 0.49 52.7 ± 25.1 0.000051 n/a n/a n/a n/a
Change from baseline -1.1 ± 6.7 -1.4 ± 7.5 0.3 ± 6.1 -1.9 ± 7.5 0.19 n/a n/a n/a n/a n/a n/a
CRQ total score
Baseline 80.4 ± 19.1 83.8 ± 20.1 77.1 ± 17.5 80.2 ± 19.3 0.11 n/a n/a n/a n/a n/a n/a
Change from baseline 10.3 ± 18.6 12.3 ± 19.2 12.7 ± 22.7 15.1 ± 10.0 0.70 n/a n/a n/a n/a n/a n/a
aClinical and demographic information for the C0168T54 COPD population is presented for all patients with baseline serum analyses performed (total) and stratified by treatment group (placebo, 3 mg/kg infliximab,
or 5 mg/kg infliximab) for patients who had serum samples analyzed for both baseline and week 24 timepoints (n = 200). P-values are presented for significance of differences among the treatment groups.
bClinical and demographic information for the BioServe COPD population, with p-values presented for significance of differences between BioServe and T54 COPD populations.
cClinical and demographic information for the healthy control populations. Ctr1, control population samples bioanalyzed in same batch as COPD samples; Ctr2, control population samples bioanalyzed independently
of the COPD and Ctr1 samples.
dP-values for the significance of differences between the indicated control population vs COPD population (T54, BioServe).
eSummary statistics are sample size (n), mean ± standard deviation, or p-value.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRQ, chronic respiratory questionnaire; FEV1, forced expiratory volume in 1 second; GOLD, Global Initiative for Chronic Obstructive Lung Disease;
n/a, not applicable.
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2cohorts relative to healthy controls for each of the 4
comparisons, whereas 2 analytes (insulin-like growth
factor [IGF]-1 and immunoglobulin [Ig]E) were signifi-
cantly lower by ≥ 50% in the COPD cohorts (Table 2,
Figure 1). CD40 ligand (CD40L), epidermal growth fac-
tor (EGF), brain-derived neurotrophic factor (BDNF),
Regulated upon Activation, Normally T-cell expressed,
and Secreted (RANTES), and myeloperoxidase were the
most highly overexpressed proteins in COPD, being on
average 10-fold greater than the levels observed for the
control cohorts. Potential batch effects in the
independently bioanalyzed Ctr2 cohort serum samples
may have impacted the results for cancer antigen (CA)
19-9 and CA125 (detailed in the online supplement -
Table S2; see Additional file 3). Differences in oral and
inhaled corticosteroid use did not significantly impact
the observed results, as described in the online supple-
ment (see Additional file 1). The ratio between the Bio-
Serve and T54 COPD cohorts had a geometric mean
(95% CI) of 1.28 (1.15-1.42), indicating a modest bias
for higher measurements in the BioServe cohort. This
difference between the COPD cohorts is well below the
Table 2 Serum analytes significantly elevated in COPD
Analyte
a Median
b Fold (COPD/control)
c FDR
d
BS T54 Ctr1 Ctr2 BS/Ctr1 T54/Ctr1 BS/Ctr2 T54/Ctr2
COPD > Control
CD40 Ligand ng/mL 2.50 0.96 0.01 0.01 250 95.9 250 95.9 < 10
-8
EGF pg/mL 699.49 230.99 14.84 3.70 47.1 15.6 189 62.4 < 10
-8
BDNF ng/mL 28.50 24.80 0.52 0.56 55.0 47.9 50.5 44.0 < 10
-8
RANTES ng/mL 18.65 15.90 1.28 1.22 14.5 12.4 15.2 13.0 < 10
-8
Myeloperoxidase ng/mL 2144.71 686.50 119.47 87.50 18.0 5.7 24.5 7.8 < 10
-8
Eotaxin pg/mL 232.50 162.50 20.50 20.50 11.3 7.9 11.3 7.9 < 10
-8
EN-RAGE ng/mL 254.97 35.60 13.40 14.50 19.0 2.7 17.6 2.5 < 10
-8
Ferritin ng/mL 166.00 113.00 18.95 28.00 8.8 6.0 5.9 4.0 < 10
-8
IL-1RA pg/mL 360.50 111.50 31.82 38.00 11.3 3.5 9.5 2.9 < 10
-8
ENA-78 ng/mL 2.07 1.68 0.32 0.35 6.5 5.2 5.9 4.8 < 10
-8
PAI-1 ng/mL 199.00 183.50 26.05 54.00 7.6 7.0 3.7 3.4 < 10
-8
MCP-1 pg/mL 558.00 483.00 170.00 100.00 3.3 2.8 5.6 4.8 < 10
-8
MIP-1beta pg/mL 341.49 259.50 99.00 87.50 3.4 2.6 3.9 3.0 < 10
-8
Thrombopoietin ng/mL 4.92 4.70 1.62 1.60 3.0 2.9 3.1 2.9 < 10
-8
TIMP-1 ng/mL 211.00 192.00 70.44 67.00 3.0 2.7 3.1 2.9 < 10
-8
IL-16 pg/mL 1174.99 440.50 233.49 273.50 5.0 1.9 4.3 1.6 < 10
-8
VEGF pg/mL 1275.00 933.00 447.00 383.50 2.9 2.1 3.3 2.4 < 10
-8
Cancer antigen 19-9 U/mL 7.19 5.94 2.11 3.30 3.4 2.8 2.2 1.8 3.7 × 10
-7 - 4.5 × 10
-4
CD40 ng/mL 1.84 1.06 0.61 0.59 3.0 1.7 3.1 1.8 < 10
-8
Creatine kinase-MB ng/mL 0.48 0.45 0.21 0.21 2.3 2.2 2.3 2.2 6.1 × 10
-7 - 8.3 × 10
-5
C-reactive protein ug/mL 4.51 3.36 2.06 1.70 2.2 1.6 2.7 2.0 4.2 × 10
-7 - 0.0074
Myoglobin ng/mL 16.00 16.10 7.14 9.30 2.2 2.3 1.7 1.7 < 10
-8 - 3.0 × 10
-8
Stem cell factor pg/mL 395.00 402.00 221.00 191.00 1.8 1.8 2.1 2.1 < 10
-8
IL-18 pg/mL 302.49 253.50 148.00 154.50 2.0 1.7 2.0 1.6 < 10
-8
TNF-RII pg/mL 5.85 5.18 3.38 3.20 1.7 1.5 1.8 1.6 < 10
-8
COPD < Control
IGF-1 ng/mL 45.30 29.30 188.55 203.00 -4.2 -6.4 -4.5 -6.9 3.0 × 10
-7 -<1 0
-8
IgE ng/mL 22.85 23.25 60.89 60.00 -2.7 -2.6 -2.6 -2.6 0.0043 - 6.0 × 10
-6
aMedian serum concentrations of the analytes in the indicated population: T54, C0168T54 COPD; BS, BioServe COPD; Ctr1, healthy control population 1; Ctr2,
healthy control population 2.
bSigned-fold = median in COPD/median in healthy control population. When median expression in COPD population was lower than in controls, the oppositeo f
the reciprocal was reported.
cFalse discovery rate (calculated from Mann-Whitney p-values) for each of the 4 COPD vs control comparisons expressed as the range of FDR values.
dAnalytes significantly associated with COPD (FDR < 0.05 and |signed-fold| > 1.5) in each of the 4 comparisons are reported, ordered by descending average fold
(COPD/control) values.
BDNF, brain-derived neurotrophic factor; COPD, chronic obstructive pulmonary disease; EGF, epidermal growth factor; ENA, epithelial-derived neutrophil
activating protein; EN-RAGE, extracellular newly identified-receptor for advanced glycation end-binding protein; FDR, false discovery rate; IgE, immunoglobulin E;
IGF, insulin-like growth factor; IL, interleukin; -MB, -muscle/brain; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PAI,
plasminogen activating factor; RA, receptor agonist; RANTES, regulated upon activation, normally T-cell expressed, and secreted; TIMP, tissue inhibitor of
metalloproteinases; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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Page 4 of 121.5-fold cut-off used for comparisons between COPD
and control cohorts. Six analytes (CD40L, IL-16, EGF,
ENRAGE, IL-1RA, and myeloperoxidase), which were
among the top overexpressed analytes associated with
COPD, had a median in the BioServe cohort 2-fold
greater than that in the T54 cohort.
To assess whether the significance of the COPD-asso-
ciated analytes was influenced by racial distribution,
race-restricted analyses were performed, pooling the 2
COPD cohorts together and the 2 control cohorts
together. When restricting the analyses to only Cauca-
sians, all COPD-associated analytes reported in Table 2
remained significant (FDR < 0.05), except for CA19-9
(FDR = 0.40) and CRP (FDR = 0.078). Similarly, in ana-
lyses restricted to only blacks, all associated analytes
retained significance, except for CA19-9 (FDR = 0.53)
and IgE (FDR = 0.13). Each of the COPD-associated
analytes reported in Table 2 remained significant when
restricting the analyses to males or females, with only
CRP in females having FDR slightly > 0.05 (online sup-
plement -Table S3; see Additional file 4).
Influence of smoking and age
Smoking and older age together are strongly associated
with risk for COPD and are therefore important to con-
sider as confounders. When restricting comparisons to
current smokers only (Figure 2, Table 3), each of the ana-
lytes significantly different between COPD and healthy
controls in the unrestricted analyses remained significant
for comparisons of the Ctr1 cohort to both the T54 and
the BioServe COPD cohorts. For comparisons with the
Ctr2 cohort, each of the analytes remained significant,
except for CA19-9, CRP, IL-18, and myoglobin. Among
the analytes not significantly associated with COPD in
the unrestricted analyses, only carcinoembryonic antigen
(CEA) was significantly elevated 60-82% in the serum
samples of current smokers with COPD compared with
healthy control current smokers (FDR = 1.2-5.0 × 10
-5).
When restricting analyses to current nonsmokers
(including ex-smokers), each of the COPD-associated
analytes reported in Table 2 remained significant for
each of the 4 comparisons, except for CRP and IgE
(data not shown). The lack of impact of smoking status
on the COPD disease associations was consistent with
limited differences between smokers and nonsmokers in
the healthy control cohorts and current and ex-smokers
in the COPD cohort (online supplement - Table S4; see
Additional file 5). Only CEA was significantly elevated
in current smokers within both the control and the
COPD cohorts when compared with nonsmokers and
ex-smokers, respectively.
Because of the potential impact of age on inflamma-
tion independent of disease, adjusting for this influence
is important for interpretation of the above results.
Therefore, statistical analyses were restricted to current
smokers aged 50-70 years, combining the 2 COPD
cohorts (n = 107) and the 2 control cohorts (n = 16).
Each of the COPD-associated analytes reported in Table
2 were significant in the age- and current smoker-
restricted comparisons, except for CA19-9, CRP, IgE,
and TNF-receptor (R) II (Figure 2).
Considering the reduced statistical power from the
smaller sample sizes for the smoking status- and age-
restricted analyses, the COPD-associated analytes reported
in Table 2 appear overall to be specific for COPD rather
than associated with smoking and older age with the pos-
sible exceptions of CA19-9, CRP, and IgE.
Correlation of inflammatory markers and disease
phenotypes
The prominent systemic inflammatory profile associated
with COPD was tested for variation across disease
Figure 1 Serum analytes associated with COPD vs controls.
Hierarchical clustering (average linkage with Euclidean distances)
was performed restricted to the analytes reported in Table 2 to be
associated with COPD vs controls. Serum concentrations were
normalized as log2 of fold over the geometric mean (Gm) of the
control cohorts and presented as a heatmap with subjects across x-
axis and analytes on y-axis. Disease status, smoking status, and
GOLD stage are represented at bottom. IGF-1, insulin-like growth
factor-1; Ig, immunoglobulin; EGF, epidermal growth factor; TNF-RII,
tumor necrosis factor-receptor II; IL, interleukin; TIMP-1, tissue
inhibitor of metalloproteinases-1; VEGF, vascular endothelial growth
factor; EN-RAGE, extracellular newly identified-receptor for advanced
glycation end-binding protein; RANTES, regulated upon activation,
normally T-cell expressed, and secreted; ENA-78, epithelial-derived
neutrophil activating protein-78; PAI-1, plasminogen activating
factor-1; MCP-1, monocyte chemoattractant protein-1; MIP-1beta,
macrophage inflammatory protein-1beta.
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Page 5 of 12severities and clinical phenotypes (Figure 3). Baseline
serum concentrations of creatine kinase-muscle/brain
(creatine kinase-MB), myoglobin, and apolipoprotein A1
were significantly (FDR < 0.05) but modestly inversely cor-
related with baseline percent-predicted FEV1 in both the
BioServe and the T54 COPD cohorts (Spearman’sr=
-0.22 to -0.27). These correlations with FEV1 were also
observed at week 24 in the T54 COPD cohort. Impor-
tantly, these correlations were independent of both inhaled
and systemic corticosteroid usage, with no patients in the
T54 COPD cohort receiving systemic steroids. Despite
nominally significant higher levels of creatine kinase-MB
and myoglobin in patients receiving systemic steroids,
adjustment for systemic steroid use in the multivariate
analyses had minimal impact on the correlations (data not
shown). Likewise, restricting the analysis to patients on
neither oral steroids nor inhaled steroids also had minimal
impact on the correlations (data not shown).
Increased serum levels of creatine kinase-MB and
myoglobin are associated with muscle tissue damage,
particularly cardiac muscle damage after cardiac events.
In the T54 COPD cohort, 22% of patients had a history
of myocardial infarction or ischemic cardiac events;
however, neither increased levels of creatine kinase-MB
and myoglobin nor decreased FEV1 were associated with
history of these cardiac events (for online supplement -
Figure S1, see Additional file 6; for the figure legend,
see Additional file 1).
Because of the nonstandardized methodology across
clinical sites and incomplete evaluations of these COPD
subcohorts with primary presentations of chronic bron-
chitis and chronic emphysema, the differential expres-
sion of the serum analytes between these 2 clinical
phenotypes was not evaluated.
Hierarchical clustering of the T54 and the BioServe
COPD cohorts was performed, restricting the analysis to
analytes significantly associated with COPD as reported
in Table 2 (for hierarchical clustering found in the online
supplement - Figure S2, see Additional file 7; for the fig-
ure legend, see Additional file 1). The BioServe cohort
was restricted to those patients with GOLD stage of ≥ II
to correspond to the T54 cohort. Demographic and clini-
cal factors, including comorbidities (data not shown), did
not segregate across clusters of COPD patients. Discrete
clusters of COPD patients defined by hierarchical cluster-
ing were not consistent between the 2 COPD cohorts.
Impact of infliximab
After establishing the systemic inflammatory and bio-
chemical profile associated with COPD, the capacity of
Figure 2 Baseline serum analyte concentrations in current smokers. The serum concentrations of the indicated analytes in healthy control
and COPD cohorts, restricted to only current smokers, are shown for subgroups < 50 (n = 36 and 22 for controls and COPD, respectively) or
between 50- to 70-years-old (n = 16 and 107 for controls and COPD, respectively). Data presented as box (median, interquartile range) and
whiskers (10
th-90
th percentiles). Dotted line indicates LDD. *COPD vs control, False discovery rate < 10
-8 within 50-70 year age group. BDNF,
brain-derived neurotrophic factor; CD40L, CD40 ligand; EGF, epidermal growth factor; IgE, immunoglobulin E.
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Page 6 of 12infliximab treatment to return this profile towards nor-
mal was examined. Changes in serum concentrations of
the inflammation-associated analytes from baseline to
week 24 were evaluated for the T54 COPD cohort (Fig-
ure 4). Only IL-8 (3 and 5 mg/kg infliximab groups
combined) and IGF-1 (5 mg/kg infliximab group only)
demonstrated trends, with high variability, for being
decreased by ≥ 50% (p = 0.035 and 0.037, respectively)
after infliximab treatment relative to placebo; however,
IGF-1 was expressed at lower levels in COPD patients
compared with controls, and IL-8 was not significantly
elevated in COPD patients. Among the analytes signifi-
cantly elevated in COPD patients, CRP and IL-16
showed trends for further elevation in the infliximab
treatment groups (p = 0.031 and 0.0020 for the 5 mg/kg
and the combined infliximab groups, respectively).
Changes in the analyte levels from baseline to week 24
also did not correlate with respective changes in FEV1
or CRQ total score (p > 0.05, data not shown). These
results are consistent with the minimal impact of inflixi-
mab on the primary (improvement in CRQ total score)
and secondary clinical outcomes (improvement in FEV1
and 6-minute walk distance). COPD patient subgroups
expressing the highest baseline levels of CRP (top quar-
tile, > 6.9 μg/ml) or TNF-alpha (top quartile, > 6.8 pg/
ml) also did not demonstrate a significant impact of
infliximab on changes in clinical and biomarker mea-
surements (Table 4).
Table 3 Serum analytes significantly elevated in COPD among older current smokers
Analyte
a T54 COPD/Ctr1
b BioServe COPD/Ctr1 T54 COPD/Ctr2 BioServe COPD/Ctr2
Fold/control
c FDR
c Fold/control FDR Fold/control FDR Fold/control FDR
COPD > Control
CD40 Ligand 102.5 < 10
-8 282.0 < 10
-8 102.5 < 10
-8 282.0 < 10
-8
EGF 16.3 < 10
-8 48.3 < 10
-8 71.5 < 10
-8 211.5 < 10
-8
BDNF 54.0 < 10
-8 63.9 < 10
-8 58.5 < 10
-8 69.3 < 10
-8
RANTES 12.0 < 10
-8 16.9 < 10
-8 14.1 < 10
-8 19.8 < 10
-8
Myeloperoxidase 6.8 < 10
-8 24.2 < 10
-8 6.5 < 10
-8 23.1 < 10
-8
Eotaxin 8.9 < 10
-8 10.8 < 10
-8 8.9 < 10
-8 10.8 < 10
-8
EN-RAGE 3.1 < 10
-8 25.5 < 10
-8 2.3 1.5 × 10
-5 19.4 < 10
-8
Ferritin 5.6 < 10
-8 8.7 < 10
-8 2.9 < 10
-8 4.5 < 10
-8
IL-1RA 5.6 < 10
-8 28.4 < 10
-8 3.5 < 10
-8 17.6 < 10
-8
ENA-78 5.9 < 10
-8 8.1 < 10
-8 7.8 < 10
-8 10.8 < 10
-8
PAI-1 7.5 < 10
-8 8.1 < 10
-8 5.3 < 10
-8 5.7 < 10
-8
MCP-1 2.8 < 10
-8 2.8 < 10
-8 4.5 < 10
-8 4.5 < 10
-8
MIP-1beta 2.5 < 10
-8 3.4 < 10
-8 2.6 < 10
-8 3.5 < 10
-8
Thrombopoietin 2.9 < 10
-8 3.1 < 10
-8 2.9 < 10
-8 3.1 < 10
-8
TIMP-1 2.7 < 10
-8 3.0 < 10
-8 3.1 < 10
-8 3.3 < 10
-8
IL-16 1.8 < 10
-8 5.7 < 10
-8 1.7 < 10
-8 5.4 < 10
-8
VEGF 2.1 < 10
-8 2.9 < 10
-8 2.6 < 10
-8 3.6 < 10
-8
Cancer antigen 19-9 2.0 0.0026 2.2 0.0084 1.6 0.18 1.8 0.25
CD40 1.7 < 10
-8 3.1 < 10
-8 1.7 < 10
-8 3.2 < 10
-8
Creatine kinase-MB 2.1 0.0023 2.3 0.0006 2.1 0.044 2.3 0.0063
C-reactive protein 1.7 0.019 2.0 0.0076 1.7 0.077 2.0 0.036
Myoglobin 2.1 9.2 × 10
-6 1.8 0.0011 1.4 0.0023 1.2 0.074
Stem cell factor 1.7 < 10
-8 1.8 < 10
-8 1.9 < 10
-8 2.1 < 10
-8
IL-18 1.7 < 10
-8 2.4 < 10
-8 1.4 4.5 × 10
-6 2.0 < 10
-8
TNF-RII 1.4 < 10
-8 1.7 < 10
-8 1.5 < 10
-8 1.8 < 10
-8
COPD < Control
IGF-1 -6.0 0.00018 -3.8 6.5 × 10
-6 -6.6 8.6 × 10
-6 -4.2 < 10
-8
IgE -4.1 0.025 -3.2 0.019 -3.4 0.0050 -2.6 0.0068
aBaseline levels of analytes reported in Table 2 to be associated with COPD vs control, restricted to current smokers between the ages of 50 and 70, inclusive.
bThe subpopulation sizes were: T54, n = 104; BioServe, n = 50; Ctr1, n = 33; Ctr2, n = 19.
cFDR and signed-fold levels in COPD over controls (fold/control) are provided for each subpopulation. FDR > 0.05 are shown in bold.
BDNF, brain-derived neurotrophic factor; COPD, chronic obstructive pulmonary disease; EGF, epidermal growth factor; ENA, epithelial-derived neutrophil
activating protein; EN-RAGE, extracellular newly identified-receptor for advanced glycation end-binding protein; FDR, false discovery rate; IgE, immunoglobulin E;
IGF, insulin-like growth factor; IL, interleukin; -MB, -muscle/brain; MCP, monocyte chemoattractant protein; MIP, macrophage inflammatory protein; PAI,
plasminogen activating factor; RA, receptor agonist; RANTES, regulated upon activation, normally T-cell expressed, and secreted; TIMP, tissue inhibitor of
metalloproteinases; TNF, tumor necrosis factor; VEGF, vascular endothelial growth factor.
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A novel robust systemic inflammatory profile is demon-
strated here to be associated with COPD. Neutrophil-
associated proteins, acute phase proteins, chemokines,
and molecules associated with muscle and tissue damage
were among the analytes associated with COPD. Impor-
tantly, these associations were independent of differ-
ences in current smoking status and age among the
groups and were evident regardless of corticosteroid
use. Despite the evident systemic inflammation, treat-
ment with infliximab did not significantly impact the
expression of these COPD-associated inflammatory mar-
kers in serum.
The associations described in this paper were derived
from 2 large, independent COPD populations compared
to a healthy control population. The associations were
further validated in a second control population that,
although bioanalyzed independently, provided a more
conservative list of associations because the analytes
were required to pass independently for both control
populations. As presented in the online supplement
-Table S5 (see Additional file 8), the majority of the
COPD-associated serum analytes are novel findings,
with differences between other broad-panel multiplex
studies of COPD[16] in terms of lack of significance or
small effects reported in those studies likely a result of
the much larger COPD cohorts and well-characterized
control cohorts employed in the current study.
In other diseases in which anti-TNF therapies have
documented clinical efficacy, anti-TNF treatment
Figure 3 Correlations of serum analyte concentrations and FEV1. Serum concentrations of the indicated analytes (y-axes) vs percent
predicted FEV1 (x-axes) are plotted for the T54 COPD cohort at baseline week 0 visit (left) and week 24 visit (middle) and for the BioServe COPD
cohort (right). Correlation coefficients and significance of correlations are reported for each plot.
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Page 8 of 12dramatically decreased CRP levels from baseline [17-20].
Serum MIP-1beta and TNF-RII, but not CRP, were pre-
viously shown to be significantly decreased by infliximab
treatment in sarcoidosis patients, with the decreases in
these biomarkers correlating with the extent of clinical
efficacy [15]. CRP was decreased, but only transiently,
and changes in CRP levels did not correlate with clinical
efficacy in that sarcoidosis study. In this study, inflixi-
mab did not significantly impact any significantly ele-
vated COPD-associated markers in the panel, including
CRP, MIP-1beta, and TNF-RII. These observations are
consistent with the lack of clinical efficacy in the study.
COPD patients expressing the highest baseline CRP or
TNF-alpha levels also did not demonstrate a significant
impact of infliximab on changes from baseline in clinical
and biomarker measurements, unlike results recently
reported for sarcoidosis [21]. The lack of immunologic
efficacy, and perhaps clinical efficacy, may be a result of
insufficient biodistribution of the drug into critical sites
of pathology, namely the airways. Alternatively, the
inflammation and pathology associated with COPD may
be largely independent of TNF-alpha, or TNF-alpha-
dependent inflammation may be already established and
insensitive to subsequent TNF-alpha neutralization and
its downstream effectors.
Acute-phase proteins, including CRP, extracellular
newly identified-receptor for advanced glycation end-
binding protein (EN-RAGE), ferritin, IL-1 receptor ago-
nist (RA), and plasminogen activating factor (PAI)-1,
were elevated in the serum samples of COPD patients.
Of these, CRP [22,23] and PAI-1[24] have been pre-
viously reported to be elevated in the serum samples of
COPD patients (online supplement - Table S5 [see
Additional file 8]) for a summary of previously reported
associations for the COPD-associated analytes listed in
Table 2). IGF-1, a protein decreased during acute-phase
reactions, was also lower in the serum samples of
COPD patients, consistent with a previous report [25].
In nearly half of the samples in the COPD cohort, TNF-
alpha levels were below LDD; however, the proportion
of subjects with TNF-alpha levels above LDD was signif-
icantly higher in both COPD cohorts versus either of
the 2 control cohorts (p = 0.0013 to < 10
-8,d a t an o t
shown). Although fibrinogen, another acute phase pro-
tein, has been described to be elevated in COPD, parti-
cularly in more severe disease[26], this protein was
generally below detection limits in the serum samples,
consistent with depletion of plasma fibrinogen during
the clotting process of serum preparation.
We observed the novel result of highly elevated circu-
lating levels of EGF in the serum samples of COPD
patients, with a median of > 50-fold increase over levels
in controls. EGF has been reported to be elevated in the
bronchial epithelial cells of COPD patients,[27] particu-
larly in damaged epithelia [28]. EGF can increase
expression of MUC5AC,[29] a mucin associated with
airway obstruction in COPD. EGF also activates fibro-
blasts and stimulates their proliferation;[27] however,
Figure 4 Changes in analyte concentrations after infliximab
treatment. The serum concentrations of the indicated analytes at
the 24-week timepoint for placebo and 3 and 5 mg/kg infliximab
treatment groups in the T54 COPD cohort are shown as signed-fold
over respective baseline concentrations. Data presented as box
(median, interquartile range) and whiskers (10
th-90
th percentiles). *p
< 0.05 for placebo vs 3 and 5 mg/kg infliximab groups combined; †
p < 0.05 for 5 mg/kg infliximab group vs placebo. IL, interleukin;
IGF-1, insulin-like growth factor-1; CRP, C-reactive protein.
Table 4 Clinical responses to infliximab
Change from baseline
a Median (IQR) p-value
b
Infliximab Placebo
TNF-alpha high subset
b
FEV1 0.0 (-4.0, 4.0) -2.3 (-6.0, 1.0) 0.11
CRQ 8.0 (0.0, 21.5) 4.0 (-1.5, 19.0) 0.34
6MWD 0.0 (-39.0, 41.0) 21.2 (-49.4, 41.7) 0.93
Dyspnea 0.0 (0.0, 2.0) 0.0 (0.0, 2.8) 0.98
log2(CRP) 0.1 (-1.1, 0.9) -0.7 (-1.5, 0.2) 0.10
CRP high subset
c
FEV1 -1.8 (-4.0, 4.0) -2.1 (-6.0, 2.0) 0.51
CRQ 17.0 (0.0, 28.5) 4.0 (0.0, 24.0) 0.38
6MWD 3.4 (-55.6, 66.0) 0.0 (-47.7, 35.0) 0.67
Dyspnea 0.0 (-3.0, 2.0) 0.0 (0.0, 2.0) 0.40
log2(CRP) -1.1 (-1.9, -0.2) -0.4 (-1.0, 0.4) 0.075
aChanges from baseline in the indicated parameter in combined infliximab (3
mg/kg + 5 mg/kg) or placebo treatment, within the specified T54 COPD
subpopulation.
bMann-Whitney p-value for combined infliximab group vs placebo group
within the indicated T54 COPD subpopulation.
cTNF-alpha high subset = top quartile for baseline serum TNF-alpha levels (>
6.8 pg/ml).
dCRP high subset = top quartile for baseline serum CRP levels (> 6.9 ug/ml).
CRP, C-reactive protein; CRQ, chronic respiratory questionnaire; FEV1, forced
expiratory volume in 1 second; IQR, interquartile range; MWD, minute walk
distance; TNF-alpha, tumor necrosis factor-alpha.
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tion of COPD, has been implicated in mucus production
in airways via activation of the EGF receptor [30].
Other proteins significantly elevated in COPD include
6 of the 10 chemokines in the panel, T-cell/antigen-pre-
senting cell co-stimulatory molecules (CD40, CD40L),
neutrophil-associated proteins (EN-RAGE, myeloperoxi-
dase, ENA-78), and thrombosis-related proteins (throm-
bopoietin, PAI-1). Other novel associations are shown in
the online supplement - Table S5 (see Additional file 8).
The robust inflammatory profile associated with
COPD appeared to be generally independent of disease
severity (GOLD classification stage and FEV1). Increased
inflammation has been reported in the lung tissue of
patients with more severe COPD;[31] however, inflam-
matory markers in the peripheral blood may reflect dis-
ease activity rather than disease severity. Mannino et al.
[32] reported in a large population-based study that ele-
vated serum CRP concentrations are associated with
COPD, with mean levels higher in patients with severe
disease compared with those with mild disease. How-
ever, correlations with FEV1 and significance across
severity levels were not formally reported. In the Bio-
Serve COPD cohort, CRP was higher in GOLD stage IV
versus stage I COPD patients, consistent with that
reported by Mannino et al. However, contrary to Man-
nino’s findings, our data showed no difference compar-
ing median CRP levels in GOLD stage III with stage I
COPD patients (data not shown). Therefore, it is possi-
ble that CRP may either be further elevated in patients
with only the most severe disease but not consistently
correlated with FEV1 or the increased CRP levels are
associated with a transient increase in disease activity (e.
g., recent exacerbation) rather than severity.
The baseline inflammatory profile also did not demon-
strate appreciable clustering with comorbidity history,
including history of myocardial infarction and ischemic
cardiac events, pneumonia, peripheral vascular disease,
and diabetes (data not shown). Hierarchical clustering
analysis also failed to identify discrete subpopulations of
COPD patients defined by patterns of serum analyte
levels that were consistent across cohorts. The lack of
correlation of the extent of systemic inflammation and
disease stage may suggest that a sustained systemic
inflammatory state occurs early in COPD progression,
perhaps before clinically-apparent onset of airway
obstruction, and persists at a similar level as disease
progresses despite worsening lung function.
Serum concentrations of both creatine kinase-MB and
myoglobin were, however, elevated in COPD patients
and inversely correlated with percent-predicted FEV1 in
COPD patients. Increased serum levels of creatine
kinase-MB and myoglobin have not been reported for
stable COPD nor have correlations with FEV1 been
observed. Increased levels of creatine kinase were
reported in peripheral muscles of COPD patients [33].
Elevated levels of creatine kinase-MB and myoglobin are
indicative of muscle damage and breakdown, particularly
cardiac muscle, suggesting that perhaps the stress on the
cardiopulmonary muscular system associated with the
obstructive airway phenotype of COPD leads to the
release of creatine kinase-MB and myoglobin into circu-
lation. Consistent with a myocardial abnormality in
COPD, reduced ventricular size and decreased cardiac
output with normal ejection fraction consistent with dia-
stolic dysfunction have been reported in COPD patients
[34]. Importantly, creatine kinase-MB and myoglobin
levels were not increased in patients with a history of
myocardial infarction or ischemic cardiac events.
Smoking is a critical risk factor for COPD and has
been reported to be associated with increased acute-
phase protein levels in circulation, independent of
COPD [35]. Although many of the smoking-elevated
proteins return to normal levels after smoking cessation,
some, like CRP, remain elevated for years; however, we
failed to observe significant elevation of inflammatory
mediators specifically in smokers without COPD. A rea-
son for this disparity may be that the controls in this
study were required to be healthy according to the rig-
orous entry criteria. This was consistent with other stu-
dies that we have performed comparing healthy smokers
and nonsmokers (unpublished internal data, Janssen
Research & Development, LLC). Conversely, in another
study that included controls who were nonobstructed
smokers, serum levels of inflammatory mediators were
elevated to an extent observed in COPD patients. These
controls, however, had some COPD-related symptoms
(sputum and coughing but not dyspnea) despite not
having clinically-defined airway obstruction (unpub-
lished internal data, Janssen Research & Development,
LLC).
In summary, COPD at an early stage of disease pro-
gression is associated with ar o b u s ts y s t e m i ci n f l a m m a -
tory profile independent of current smoking status.
Despite the inflammation associated with COPD, includ-
ing significant elevation of CRP, TNF-alpha, and other
acute-phase proteins, treatment with infliximab did not
significantly impact this inflammatory profile. Inflixi-
mab’s lack of biochemical efficacy was consistent with
its lack of clinical efficacy in COPD patients. The reason
for the lack of both biochemical and clinical efficacy
remains unclear, although possible explanations include
TNF-alpha being a redundant contributor to inflamma-
tion in COPD and infliximab not reaching the site of
local inflammation (airways) at sufficient levels to effi-
ciently neutralize the activity of TNF-alpha.
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Additional file 1: Online Supplement. Describes healthy controls
exclusion criteria and serum analyte concentrations measurements in the
Methods, corticosteroid influence and potential batch effects in the
Results, salient References for this supplement, and the figure legends for
online supplement Figures S1 and S2, found in Additional files 6 and 7.
Additional file 2: Online Supplement - Table S1. Least detectable
doses for analytes in Rules-Based Medicine Human MAP v1.6 panel.
Analytes’ least detectable doses in the Rules-Based Medicine MAP v. 1.6
panel.
Additional file 3: Online Supplement- Table S2. Analytes
demonstrating potential batch effects. Analytes’ demonstrating potential
batch effects.
Additional file 4: Online Supplement - Table S3. Gender- and race-
restricted analyses for associations with COPD. COPD associations with
gender- and race-restricted analyses.
Additional file 5: Online Supplement - Table S4. Associations of
baseline analyte levels with smoking status. Baseline analyte levels and
their associations with smoking status.
Additional file 6: Online Supplement - Figure S1. Associations of
biomarkers with history of myocardial event. Three graphs show serum
levels of patients with a history of myocardial infarction or cardiac
ischemia.
Additional file 7: Online Supplement - Figure S2. Supervised
clustering within COPD populations. Heatmap of supervised clustering
within populations with COPD.
Additional file 8: Online Supplement - Table S5. Previous reports for
COPD-associated analytes identified herein. Compares previously
reported and identified COPD-associated analytes.
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